Showing results (61-70 of 109) with videos related to
Sort By:
Pageof 11
Journal for Immunotherapy of Cancer|June 20, 2020
Chronic immune checkpoint inhibitor pneumonitisJarushka Naidoo, Tricia R Cottrell, Evan J Lipson, et al.Cell Reports|September 10, 2024
Aged fibroblast-derived extracellular vesicles promote angiogenesis in melanomaLaura Hüser, Yash Chhabra, Olesia Gololobova, et al.Cancer Immunology Research|August 26, 2021
Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker DiscoveryNicolas A Giraldo, Sneha Berry, Etienne Becht, et al.Journal for Immunotherapy of Cancer|February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial DataGeorgina V Long, Evan J Lipson, F Stephen Hodi, et al.European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateEvan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.Science Immunology|July 19, 2020
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 sheddingLawrence P Andrews, Ashwin Somasundaram, Jessica M Moskovitz, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|July 25, 2017
Melanoma subtypes demonstrate distinct PD-L1 expression profilesGenevieve J Kaunitz, Tricia R Cottrell, Mohammed Lilo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.Cancer Immunology Research|May 19, 2022
Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T CellsAshwin Somasundaram, Anthony R Cillo, Caleb Lampenfeld, et al.Pageof 11